A Real-word, single-center study analysing efficacy and safety of Ocrelizumab in patients with progressive multiple sclerosis
Latest Information Update: 11 Jun 2021
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 11 Jun 2021 New trial record
- 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology